InspireMD sales up 231% in mixed-bag Q2 results

InspireMD (NYSE:NSPR) posted second-quarter results this week that beat the earnings consensus on Wall Street but missed revenue estimates.

The Tel Aviv, Israel-based carotid stenting company reported losses of $3.5 million, or -46¢ per share, on sales of $1.03 million for the three months ended June 30, for a sales growth of 231.63% compared with Q2 2020.

InspireMD’s earnings of -46¢ were 17¢ ahead of The Street, where analysts were looking for $1.1 million in sales.

“We are pleased with our second-quarter results that showed strong procedural recovery and market demand of CGuard EPS. Our ultimate goal is to change the standard of care in the treatment of carotid artery disease away from surgical endarterectomy to the minimally invasive use of CGuard EPS carotid stent system,” CEO Marvin Slosman said in a news release.

The company did not offer financial guidance for the 2021 year.

Shares in NSPR were up 4.04% to $4.12 apiece i…

Read more
  • 0

InspireMD dips despite Street-beating Q1

InspireMD (NYSE:NSPR) shares slid today despite first-quarter results that topped the consensus forecast.

The Tel Aviv, Israel-based company posted losses of -$3.2 million, or -53¢ per share, on sales of $1 million for the three months ended March 31, 2021, for a -64% bottom-line slide on a sales decline of -2.7%.

InspireMD’s EPS of -53¢ came in 7¢ ahead of Wall Street, where analysts were looking for sales of $900,000.

“Our persistent and tireless focus on execution continues as we build on our quest to change the standard of care in the treatment of carotid artery disease and stroke prevention, with CGuard EPS and our novel Micronet mesh,” InspireMD CEO Marvin Slosman said in a news release. “Our Q1 achievements have set up 2021 to be a meaningful year of progress toward our goals of global expansion, commercial revenue growth, progress toward FDA approval, growing our unmatched body of clinical evidence, and differentiating CGuard as…

Read more
  • 0

InspireMD wins FDA approval for carotid stent system study

InspireMD today said it received FDA approval to proceed with a pivotal study of its CGuard Carotid Stent System.

The investigational device exemption from the FDA will allow the company to study the device for the prevention of stroke in patients in the U.S.

Get the full story on our sister site, Medical Tubing + Extrusion.

Read more
  • 0

InspireMD posts Street-beating Q2 results

InspireMD (NYSE:NSPR) posted second-quarter results today that beat the consensus on Wall Street.

The Tel Aviv, Israel-based company reported losses of $2.5 million, on sales of $313,000 for the three months ended June 30, for a sales loss of -76.9% compared with Q2 2019.

Earnings per share were -20¢, 15¢ ahead of The Street, where analysts were looking for sales of $203,000.

“COVID-19 placed significant pressure on the operations of healthcare facilities worldwide, resulting in interruptions in elective procedure volumes, including critical carotid artery treatments. However, we are encouraged by the gradual resumption of these crucial procedures in a growing number of our key markets in Europe and other territories, and we look forward to this expansion taking hold in South America as well. We are also buoyed by the scientific validation we continue to receive in both peer-reviewed publications and opportunities to present at medical conferences where …

Read more
  • 0